SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.
Researchers developed a cell-free DNA blood test that accurately distinguishes ALS from other neurological diseases and tracks progression.
Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease that affects the neurons in the brain and spinal cord. In the United States alone there are ...
Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...
New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disorder causing motor neuron death, leading to muscle ...
Amryta’s Sodesta gene therapy gains accelerated approval for ALS The Food and Drug Administration has granted accelerated ...
Qure NV (QURE) reports significant progress in Huntington's disease treatment but faces hurdles with FDA approval.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback